Novo Nordisk's Ambitious Growth Plan Fails to Reassure Investors
During its Capital Markets Day in London, Novo Nordisk presented an ambitious long-term growth strategy through 2030. The company aims for revenue growth aligned with major pharmaceutical peers and plans to launch more than five potential blockbuster drugs by 2030. Despite these goals, investors remained unconvinced due to a lack of clarity on how the firm will replace its flagship drug semaglutide as patent expirations approach in the early 2030s. The company also outlined plans for over DKK150 billion ($23 billion) in risk-adjusted sales by 2035 and a significant expansion of patient reach. However, concerns about pricing pressure from competitors like Eli Lilly and recent clinical setbacks weighed heavily on investor sentiment. Shares fell as much as 9% during the event due to these uncertainties. Positive data for cagriSema in obesity trials was noted but not enough to offset broader skepticism around Novo's long-term strategy.
Topics: investor sentiment long-term strategy patent expiration pipeline